Over the past two decades interest in mitral valve regurgitation has increased as a result of the development of new technologies that have expanded the number of patients who can potentially benefit from mitral regurgitation treatments. To develop new devices for the treatment of mitral regurgitation, the focus has been placed on the functional anatomy and pathophysiology of the mitral valve, with the use of the most advanced methods of cardiac imaging that allow the best visualization of the mitral valve and a perfect understanding of the complexity of a specific disease. Mitral regurgitation is still underdiagnosed and undertreated in a substantial number of patients who have poor survival. Therefore, the priority should be to identify and treat these patients to increase their survival and quality of life. To achieve this goal, general physicians and cardiologists must be aware of all the treatment options that are currently available in dedicated centres of excellence. Patients referred to these centres can benefit from a tailored heart team-based approach. The aim of this Review is to analyse the basic principles of mitral regurgitation, discussing new concepts on the pathophysiology of the mitral valve that have been developed to facilitate the selection of patients for transcatheter procedures. We also describe the indications and timing of treatment, contemporary surgical and transcatheter techniques and the heart team approach, and highlight the need for centres of excellence.
Mitral regurgitation has generated growing interest over the past 20 years; nevertheless, mitral regurgitation is still underdiagnosed and undertreated in a large number of patients who have poor survival and quality of life.
Given the different aetiologies, lesions and pathophysiology underlying mitral regurgitation, a proper understanding of the characteristics of the disease is mandatory to plan the correct treatment.
The availability of novel and sophisticated multimodality imaging allows an accurate evaluation of the mitral valve complex, guiding the diagnosis, timing of intervention and treatment with surgical techniques or percutaneous technologies.
Surgical mitral valve repair is the gold-standard treatment in severe primary (mainly degenerative) mitral regurgitation, with excellent durability and restoration of normal life expectancy and good quality of life.
In secondary mitral regurgitation, the heart team should identify patients who are likely to benefit from treatment, given that a benefit has been demonstrated only in highly selected patients.
In the current era, given the wide range of imaging modalities and therapeutic options, offering each patient the most appropriate and tailored approach according to the individual aetiology, pathophysiology and risk profile is essential.
This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Dziadzko, V. et al. Causes and mechanisms of isolated mitral regurgitation in the community: clinical context and outcome. Eur. Heart J. 40, 2194–2202 (2019).
Delling, F. N. et al. Evolution of mitral valve prolapse: insights from the Framingham Heart Study. Circulation 133, 1688–1695 (2016).
Nkomo, V. T. et al. Burden of valvular heart diseases: a population-based study. Lancet 368, 1005–1011 (2006).
D’Arcy, J. L. et al. Large-scale community echocardiographic screening reveals a major burden of undiagnosed valvular heart disease in older people: the OxVALVE Population Cohort Study. Eur. Heart J. 37, 3515–3522 (2016).
Mirabel, M. et al. What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur. Heart J. 28, 1358–1365 (2007).
Dal-Bianco, J. P. & Levine, R. A. Anatomy of the mitral valve apparatus: role of 2D and 3D echocardiography. Cardiol. Clin. 31, 151–164 (2013).
Maréchaux, S. et al. Functional anatomy and pathophysiologic principles in mitral regurgitation: non-invasive assessment. Prog. Cardiovasc. Dis. 60, 289–304 (2017).
Weir-McCall, J. R. et al. Mitral valve imaging with CT: relationship with transcatheter mitral valve interventions. Radiology 288, 638–655 (2018).
Prendergast, B. D. et al. Transcatheter heart valve interventions: where are we? Where are we going? Eur. Heart J. 40, 422–440 (2019).
Silbiger, J. J. & Bazaz, R. Contemporary insights into the functional anatomy of the mitral valve. Am. Heart J. 158, 887–895 (2009).
Carpentier, A. Cardiac valve surgery — the ‘French correction’. J. Thorac. Cardiovasc. Surg. 86, 323–337 (1983).
Anyanwu, A. C. & Adams, D. H. Etiologic classification of degenerative mitral valve disease: Barlow’s disease and fibroelastic deficiency. Semin. Thorac. Cardiovasc. Surg. 19, 90–96 (2007).
Enriquez-Sarano, M., Akins, C. W. & Vahanian, A. Mitral regurgitation. Lancet 373, 1382–1394 (2009).
Carpentier, A., Lacour-Gayet, F. & Camilleri, J. Fibroelastic dysplasia of the mitral valve: an anatomical and clinical entity. Circulation 3, 307 (1982).
Barlow, J. B. & Pocock, W. A. The significance of late systolic murmurs and mid-late systolic clicks. Md. State Med. J. 12, 76–77 (1963).
Adams, D. H., Anyanwu, A. C., Sugeng, L. & Lang, R. M. Degenerative mitral valve regurgitation: surgical echocardiography. Curr. Cardiol. Rep. 10, 226–232 (2008).
Mills, W. R. et al. Biomechanical and echocardiographic characterization of flail mitral leaflet due to myxomatous disease: further evidence for early surgical intervention. Am. Heart J. 148, 144–150 (2004).
Abramowitz, Y., Jilaihawi, H., Chakravarty, T., Mack, M. J. & Makkar, R. R. Mitral annulus calcification. J. Am. Coll. Cardiol. 66, 1934–1941 (2015).
Remenyi, B., Carapetis, J., Wyber, R., Taubert, K. & Mayosi, B. M. Position statement of the World Heart Federation on the prevention and control of rheumatic heart disease. Nat. Rev. Cardiol. 10, 284–292 (2013).
Andell, P. et al. Epidemiology of valvular heart disease in a Swedish nationwide hospital-based register study. Heart 103, 1696–1703 (2017).
Carabello, B. A. Mitral regurgitation: basic pathophysiologic principles. Mod. Concepts Cardiovasc. Dis. 57, 53–58 (1988).
West, J. B. & Mathieu-Costello, O. Vulnerability of pulmonary capillaries in heart disease. Circulation 92, 622–631 (1995).
Rich, S. & Rabinovitch, M. Diagnosis and treatment of secondary (non-category 1) pulmonary hypertension. Circulation 118, 2190–2199 (2008).
Champion, H. C., Michelakis, E. D. & Hassoun, P. M. Comprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit: state of the art and clinical and research implications. Circulation 120, 992–1007 (2009).
Gaasch, W. H. & Meyer, T. E. Left ventricular response to mitral regurgitation: implications for management. Circulation 118, 2298–2303 (2008).
Bennett, S. et al. Mitral annular disjunction: a systematic review of the literature. Echocardiography. 36, 1549–1558 (2019).
Perazzolo Marra, M. et al. Morphofunctional abnormalities of mitral annulus and arrhythmic mitral valve prolapse. Circ. Cardiovasc. Imaging. 9, e005030 (2016).
Basso, C. et al. Arrhythmic mitral valve prolapse and sudden cardiac death. Circulation 132, 556–566 (2015). This paper provides specific data on patients with mitral valve prolapse and sudden cardiac death from a very large cardiology pathology registry.
Dejgaard, L. A. et al. The mitral annulus disjunction arrhythmic syndrome. J. Am. Coll. Cardiol. 72, 1600–1609 (2018).
Eriksson, M. J. et al. Mitral annular disjunction in advanced myxomatous mitral valve disease: echocardiographic detection and surgical correction. J. Am. Soc. Echocardiogr. 18, 1014–1022 (2005).
Essayagh, B. et al. Usefulness of 3-Tesla cardiac magnetic resonance to detect mitral annular disjunction in patients with mitral valve prolapse. Am. J. Cardiol. 124, 1725–1730 (2019).
Asgar, A. W., Mack, M. J. & Stone, G. W. Secondary mitral regurgitation in heart failure: pathophysiology, prognosis, and therapeutic considerations. J. Am. Coll. Cardiol. 65, 1231–1248 (2015).
Gertz, Z. M. et al. Evidence of atrial functional mitral regurgitation due to atrial fibrillation: reversal with arrhythmia control. J. Am. Coll. Cardiol. 58, 1474–1481 (2011).
Sherrid, M. V., Balaram, S., Kim, B., Axel, L. & Swistel, D. G. The mitral valve in obstructive hypertrophic cardiomyopathy: a test in context. J. Am. Coll. Cardiol. 67, 1846–1858 (2016). An in-depth review discussing the involvement of the mitral valve in the context of obstructive hypertrophic cardiomyopathy.
Rossi, A. et al. Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy. Heart 97, 1675–1680 (2011).
Delgado, V. & Bax, J. J. Atrial functional mitral regurgitation: from mitral annulus dilatation to insufficient leaflet remodeling. Circ. Cardiovasc. Imaging. 10, e006239 (2017).
Hagège, A. A. et al. The mitral valve in hypertrophic cardiomyopathy: old versus new concepts. J. Cardiovasc. Transl Res. 4, 757–766 (2011).
Bhardwaj, B. et al. Outcomes and hospital utilization in patients with papillary muscle rupture associated with acute myocardial infarction. Am. J. Cardiol. 125, 1020–1025 (2020).
Grigioni, F., Enriquez-Sarano, M., Zehr, K. J., Bailey, K. R. & Tajik, A. J. Ischemic mitral regurgitation: long-term outcome and prognostic complications with quantitative Doppler assessment. Circulation 103, 1759–1764 (2001).
Piérard, L. A. & Carabello, B. A. Ischaemic mitral regurgitation: pathophysiology, outcomes and the conundrum of treatment. Eur. Heart J. 31, 2996–3005 (2010).
Lancellotti, P., Zamorano, J. L. & Vannan, M. A. Imaging challenges in secondary mitral regurgitation: unsolved issues and perspectives. Circ. Cardiovasc. Imaging 7, 735–746 (2014).
He, S., Fontaine, A. A., Schwammenthal, E., Yoganathan, A. P. & Levine, R. A. Integrated mechanism for functional mitral regurgitation: leaflet restriction versus coapting force: in vitro studies. Circulation 96, 1826–1834 (1997).
Beaudoin, J. et al. Mitral valve enlargement in chronic aortic regurgitation as a compensatory mechanism to prevent functional mitral regurgitation in the dilated left ventricle. J. Am. Coll. Cardiol. 61, 1809–1816 (2013).
Tibayan, F. A. et al. Tenting volume: three-dimensional assessment of geometric perturbations in functional mitral regurgitation and implications for surgical repair. J. Heart Valve. Dis. 16, 1–7 (2007).
Spartera, M. et al. Role of cardiac dyssynchrony and resynchronization therapy in functional mitral regurgitation. Eur. Heart J. Cardiovasc. Imaging 17, 471–480 (2016). This paper discusses how cardiac resynchronization therapy can have therapeutic effects on secondary mitral regurgitation.
Ling, L. H., Kistler, P. M., Kalman, J. M., Schilling, R. J. & Hunter, R. J. Comorbidity of atrial fibrillation and heart failure. Nat. Rev. Cardiol. 13, 131–147 (2016). A comprehensive review that highlights how the association between atrial fibrillation and heart failure presents unique diagnostic and management challenges.
Beeri, R. et al. Mitral regurgitation augments post-myocardial infarction remodeling failure of hypertrophic compensation. J. Am. Coll. Cardiol. 51, 476–486 (2008).
Daniels, L. B. et al. Influence of age, race, sex, and body mass index on interpretation of midregional pro atrial natriuretic peptide for the diagnosis of acute heart failure: results from the BACH multinational study. Eur. J. Heart Fail. 14, 22–31 (2012).
Adlbrecht, C. et al. Prognostic value of plasma midregional pro-adrenomedullin and C-terminal-pro-endothelin-1 in chronic heart failure outpatients. Eur. J. Heart Fail. 11, 361–366 (2009).
Volpe, M., Battistoni, A. & Rubattu, S. Natriuretic peptides in heart failure: current achievements and future perspectives. Int. J. Cardiol. 281, 186–189 (2019).
Bäcka, M., Pizarro, R. & Clavel, M. A. Biomarkers in mitral regurgitation. Prog. Cardiovasc. Dis. 60, 334–341 (2017). This review focuses on the usefulness of biomarkers in evaluating and managing patients with mitral regurgitation, particularly revealing subclinical and/or very early damage induced by LV volume overload.
Dini, F. L. et al. Plasma N-terminal protype-B natriuretic peptide levels in risk assessment of patients with mitral regurgitation secondary to ischemic and nonischemic dilated cardiomyopathy. Am. Heart J. 155, 1121–1127 (2008).
Ciarka, A. et al. Predictors of mitral regurgitation recurrence in patients with heart failure undergoing mitral valve annuloplasty. Am. J. Cardiol. 106, 395–401 (2010).
Kron, I. L. et al. Predicting recurrent mitral regurgitation after mitral valve repair for severe ischemic mitral regurgitation. J. Thorac. Cardiovasc. Surg. 149, 752–761 (2015).
Agricola, E. et al. Echocardiographic classification of chronic ischemic mitral regurgitation caused by restricted motion according to tethering pattern. Eur. J. Echocardiogr. 5, 326–334 (2004).
Gaasch, W. H. & Meyer, T. E. Secondary mitral regurgitation (part 1): volumetric quantification and analysis. Heart 104, 634–638 (2018).
Benjamin, E. J. et al. Heart disease and stroke statistics — 2017 update: a report from the American Heart Association. Circulation 135, e146–e603 (2017).
Krijthe, B. P. et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur. Heart J. 34, 2746–2751 (2013).
Abe, Y. et al. Prevalence and prognostic significance of functional mitral and tricuspid regurgitation despite preserved left ventricular ejection fraction in atrial fibrillation patients. Circ. J. 82, 1451–1458 (2018).
Silbiger, J. J. Does left atrial enlargement contribute to mitral leaflet tethering in patients with functional mitral regurgitation? Proposed role of atriogenic leaflet tethering. Echocardiography 31, 1310–1311 (2014).
Reddy, S. T. et al. Mitral regurgitation recovery and atrial reverse remodeling following pulmonary vein isolation procedure in patients with atrial fibrillation: a clinical observation proof-of-concept cardiac MRI study. J. Interv. Card. Electrophysiol. 37, 3017–3025 (2013).
Takahashi, Y. et al. Mitral valve repair for atrial functional mitral regurgitation in patients with chronic atrial fibrillation. Interact. Cardiovasc. Thorac. Surg. 21, 163–168 (2015).
Ro, R. et al. Vector flow mapping in obstructive hypertrophic cardiomyopathy to assess the relationship of early systolic left ventricular flow and the mitral valve. J. Am. Coll. Cardiol. 64, 1984–1995 (2014).
Klues, H. G., Maron, B. J., Dollar, A. L. & Roberts, W. C. Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy. Circulation 85, 1651–1660 (1992).
Maron, M. S. et al. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Circulation 124, 40–47 (2011).
Vassileva, C. M. et al. Long-term survival of patients undergoing mitral valve repair and replacement: a longitudinal analysis of Medicare fee-for-service beneficiaries. Circulation 127, 1870–1876 (2013).
Vohra, H. A. et al. Outcome after redo-mitral valve replacement in adult patients: a 10-year single-centre experience. Interact. Cardiovasc. Thorac. Surg. 14, 575–579 (2012).
Bourguignon, T. et al. Very late outcomes for mitral valve replacement with the Carpentier-Edwards pericardial bioprosthesis: 25-year follow-up of 450 implantations. J. Thorac. Cardiovasc. Surg. 148, 2004–2011 (2014).
Pibarot, P. & Dumesnil, J. G. Prosthetic heart valves: selection of the optimal prosthesis and long-term management. Circulation 119, 1034–1048 (2009).
Singhal, P., Luk, A. & Butany, J. Bioprosthetic heart valves: impact of implantation on biomaterials. ISRN Biomater. 2013, 728791 (2013).
Hwang, H. Y. et al. Paravalvular leak after mitral valve replacement: 20-year follow-up. Ann. Thorac. Surg. 100, 1347–1352 (2015).
Ruiz, C. E. et al. Clinical trial principles and endpoint definitions for paravalvular leaks in surgical prosthesis: an expert statement. J. Am. Coll. Cardiol. 69, 2067–2087 (2017).
Ionescu, A., Fraser, A. G. & Butchart, E. G. Prevalence and clinical significance of incidental paraprosthetic valvar regurgitation: a prospective study using transoesophageal echocardiography. Heart 89, 1316–1321 (2003).
O’Rourke, D. J. et al. Outcome of mild periprosthetic regurgitation detected by intraoperative transesophageal echocardiography. J. Am. Coll. Cardiol. 38, 163–166 (2001).
Flameng, W., Meuris, B., Herijgers, P. & Herregods, M. C. Durability of mitral valve repair in Barlow disease versus fibroelastic deficiency. J. Thorac. Cardiovasc. Surg. 135, 274–282 (2008).
Suri, R. M. et al. Recurrent mitral regurgitation after repair: should the mitral valve be re-repaired? J. Thorac. Cardiovasc. Surg. 132, 1390–1397 (2006).
Anyanwu, A. C. & Adams, D. H. Why do mitral valve repairs fail? J. Am. Soc. Echocardiogr. 22, 1265–1268 (2009).
Zoghbi, W. A. et al. Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance. J. Am. Soc. Echocardiogr. 30, 303–371 (2017). These are the latest recommendations from the American Society of Echocardiography in collaboration with the Society for Cardiovascular Magnetic Resonance addressing the non-invasive evaluation of native valvular regurgitation.
Nishimura, R. A. et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart diseases. Circulation 135, e1159–e1195 (2017). This article includes the latest US guidelines addressing the management of valvular heart diseases.
Baumgartner, H. et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur. Heart J. 38, 2739–2791 (2017). This article includes the latest European guidelines addressing the management of valvular heart diseases.
Kim, H. M. et al. Myocardial strain in prediction of outcomes after surgery for severe mitral regurgitation. JACC Cardiovasc. Imaging 11, 1235–1244 (2018).
Faletra, F. F., Leo, L. A. & Paiocchi, V. L. Anatomy of mitral annulus: insight from non-invasive imaging techniques. Eur. Heart J. Cardiovasc. Imaging 20, 843–857 (2019). An extensive review that highlights the peculiar aspects of the mitral annulus as they appear with the use of different imaging techniques and discusses clinical implications related to this complex structure.
Lee, A. P. et al. Functional implication of mitral annular disjunction in mitral valve prolapse: a quantitative dynamic 3D echocardiographic study. JACC Cardiovasc. Imaging 10, 1424–1433 (2017).
Sugeng, L. et al. Accuracy of mitral valve area measurements using transthoracic rapid freehand 3-dimensional scanning: comparison with noninvasive and invasive methods. J. Am. Soc. Echocardiogr. 16, 1292–1300 (2003).
Blanke, P. et al. Multimodality imaging in the context of transcatheter mitral valve replacement: establishing consensus among modalities and disciplines. JACC Cardiovasc. Imaging 8, 1191–1208 (2015).
Heo, R. et al. Clinical implications of three-dimensional real-time color Doppler transthoracic echocardiography in quantifying mitral regurgitation: a comparison with conventional two-dimensional methods. J. Am. Soc. Echocardiogr. 30, 393–403 (2017).
Zeng, X. et al. Diagnostic value of vena contracta area in the quantification of mitral regurgitation severity by color Doppler 3D echocardiography. Circ. Cardiovasc. Imaging 4, 506–513 (2011).
Nolan, M. T. & Thavendiranathan, P. Automated quantification in echocardiography. JACC Cardiovasc. Imaging 12, 1073–1092 (2019).
Faletra, F. F. et al. Echocardiographic-fluoroscopic fusion imaging for transcatheter mitral valve repair guidance. Eur. Heart J. Cardiovasc. Imaging 19, 715–726 (2018).
Myerson, S. G. et al. Determination of clinical outcome in mitral regurgitation with cardiovascular magnetic resonance quantification. Circulation 133, 2287–2296 (2016). This paper shows that CMR can be an adjunctive tool for the management of patients with mitral regurgitation, identifying those who develop symptoms or other indications for surgery.
Han, Y. et al. Cardiovascular magnetic resonance characterization of mitral valve prolapse. JACC Cardiovasc. Imaging 1, 294–303 (2008).
Van De Heyning, C. M. et al. Late gadolinium enhancement CMR in primary mitral regurgitation. Eur. J. Clin. Invest. 44, 840–847 (2014).
Edwards, N. C. et al. Quantification of left ventricular interstitial fibrosis in asymptomatic chronic primary degenerative mitral regurgitation. Circ. Cardiovasc. Imaging 7, 946–953 (2014).
Miller, M. A. et al. Arrhythmic mitral valve prolapse. J. Am. Coll. Cardiol. 72, 2904–2914 (2018).
Cavalcante, J. L. et al. Prognostic impact of ischemic mitral regurgitation severity and myocardial infarct quantification by cardiovascular magnetic resonance. JACC Cardiovasc. Imaging https://doi.org/10.1016/j.jcmg.2019.11.008 (2019).
Liu, B., Edwards, N. C., Pennell, D. & Steeds, R. P. The evolving role of cardiac magnetic resonance in primary mitral regurgitation: ready for prime time? Eur. Heart J. Cardiovasc. Imaging 20, 123–130 (2019).
Blanke, P. et al. Mitral annular evaluation with CT in the context of transcatheter mitral valve replacement. JACC Cardiovasc. Imaging 8, 612–615 (2015).
Choure, A. J. et al. In vivo analysis of the anatomical relationship of coronary sinus to mitral annulus and left circumflex coronary artery using cardiac multidetector computed tomography: implications for percutaneous coronary sinus mitral annuloplasty. J. Am. Coll. Cardiol. 48, 1938–1945 (2006).
Van Mieghem, N. M. et al. Computed tomography optimised fluoroscopy guidance for transcatheter mitral therapies. EuroIntervention 11, 1428–1431 (2016).
Blanke, P. et al. Predicting LVOT obstruction in transcatheter mitral valve implantation: concept of the neo-LVOT. JACC Cardiovasc. Imaging 10, 482–485 (2017).
Van Rosendael, P. J. et al. Integrated imaging of echocardiography and computed tomography to grade mitral regurgitation severity in patients undergoing transcatheter aortic valve implantation. Eur. Heart J. 38, 2221–2226 (2017).
Biner, S. et al. Reproducibility of proximal isovelocity surface area, vena contracta, and regurgitant jet area for assessment of mitral regurgitation severity. JACC Cardiovasc. Imaging 3, 235–243 (2010).
Grayburn, P. A. et al. Defining “severe” secondary mitral regurgitation: emphasizing an integrated approach. J. Am. Coll. Cardiol. 64, 2792–2801 (2014).
Di Tullio, M. R. & Homma, S. Direct measurement of multiple vena contracta areas for assessing the severity of mitral regurgitation using 3D TEE. JACC Cardiovasc. Imaging 5, 669–676 (2012).
Shanks, M. et al. Quantitative assessment of mitral regurgitation comparison between three-dimensional transesophageal echocardiography and magnetic resonance imaging. Circ. Cardiovasc. Imaging 3, 694–700 (2010).
Lancellotti, P. et al. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging. Eur. Heart J. Cardiovasc. Imaging 14, 611–614 (2013). This article includes the latest recommendations from the European Association of Cardiovascular Imaging for the echocardiographic assessment of native valvular regurgitation.
Dujardin, K. S. et al. Grading of mitral regurgitation by quantitative Doppler echocardiography: calibration by left ventricular angiography in routine clinical practice. Circulation 96, 3409–3415 (1997).
Uretsky, S. et al. Quantification of left ventricular remodeling in response to isolated aortic or mitral regurgitation. J. Cardiovasc. Magn. Reson. 12, 32 (2010).
Penicka, M. et al. Prognostic implications of magnetic resonance-derived quantification in asymptomatic patients with organic mitral regurgitation: comparison with Doppler echocardiography-derived integrative approach. Circulation 137, 1349–1360 (2018).
Harris, A. W. et al. Cardiac magnetic resonance imaging versus transthoracic echocardiography for prediction of outcomes in chronic aortic or mitral regurgitation. Am. J. Cardiol. 119, 1074–1081 (2017).
Khattar, R. S. & Senior, R. Stress echocardiography in the assessment of native valve disease. Heart 105, 1034–1043 (2019).
Lancellotti, P. et al. The clinical use of stress echocardiography in non-ischaemic heart disease: recommendations from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J. Am. Soc. Echocardiogr. 30, 101–138 (2017).
Magne, J. et al. Impact of exercise pulmonary hypertension on postoperative outcome in primary mitral regurgitation. Heart 101, 391–396 (2015).
Lee, R. et al. Functional and prognostic implications of left ventricular contractile reserve in patients with asymptomatic severe mitral regurgitation. Heart 91, 1407–1412 (2005).
Kusunose, K., Popovic´, Z. B., Motoki, H. & Marwick, T. H. Prognostic significance of exercise-induced right ventricular dysfunction in asymptomatic degenerative mitral regurgitation. Circ. Cardiovasc. Imaging 6, 167–176 (2013).
Utsunomiya, H. et al. Exercise-stress echocardiography and effort intolerance in asymptomatic/minimally symptomatic patients with degenerative mitral regurgitation combined invasive–noninvasive hemodynamic monitoring. Circ. Cardiovasc. Imaging 11, e007282 (2018).
Dulgheru, R. et al. Exercise testing in mitral regurgitation. Prog. Cardiovasc. Dis. 60, 342–350 (2017).
Lancellotti, P., Troisfontaines, P., Toussaint, A. & Pierard, L. A. Prognostic importance of exercise-induced changes in mitral regurgitation in patients with chronic ischemic left ventricular dysfunction. Circulation 108, 1713–1717 (2003).
Lancellotti, P., Gérard, P. L. & Piérard, L. A. Long-term outcome of patients with heart failure and dynamic functional mitral regurgitation. Eur. Heart J. 26, 1528–1532 (2005).
Tribouilloy, C. M. et al. Impact of preoperative symptoms on survival after surgical correction of organic mitral regurgitation: rationale for optimizing surgical indications. Circulation 99, 400–405 (1999).
Nashef, S. A. et al. European system for cardiac operative risk evaluation (EuroSCORE). Eur. J. Cardiothorac. Surg. 16, 9–13 (1999).
Shahian, D. M. & Edwards, F. H. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: introduction. Ann. Thorac. Surg. 88 (Suppl. 1), 1 (2009).
Mack, M. J. Risk scores for predicting outcomes in valvular heart disease: how useful? Curr. Cardiol. Rep. 13, 107–112 (2011).
Nashef, S. A. et al. EuroSCORE II. Eur. J. Cardiothorac. Surg. 41, 734–744 (2012).
Barili, F. et al. Reliability of new scores in predicting perioperative mortality after mitral valve surgery. J. Thorac. Cardiovasc. Surg. 147, 1008–1012 (2014).
Carabello, B. A. The current therapy for mitral regurgitation. J. Am. Coll. Cardiol. 52, 319–326 (2008).
Ahmed, M. I., Aban, I. & Lloyd, S. G. A randomized controlled phase IIb trial of beta(1)-receptor blockade for chronic degenerative mitral regurgitation. J. Am. Coll. Cardiol. 9, 833–838 (2012).
He, Z. et al. Efficacy and safety of supramaximal titrated inhibition of renin-angiotensin-aldosterone system in idiopathic dilated cardiomyopathy. ESC. Heart Fail. 2, 129–138 (2015).
Packer, M. & Grayburn, P. A. Neurohormonal and transcatheter repair strategies for proportionate and disproportionate functional mitral regurgitation in heart failure. JACC Heart. Fail. 7, 518–522 (2019).
Nasser, R. et al. Evolution of functional mitral regurgitation and prognosis in medically managed heart failure patients with reduced ejection fraction. JACC Heart. Fail. 5, 652–659 (2017).
Kang, D. H. et al. Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation. Circulation 139, 1354–1365 (2019).
Cipriani, M. et al. Prognostic implications of mitral regurgitation in patients after cardiac resynchronization therapy. Eur. J. Heart Fail. 18, 1060–1068 (2016).
Onishi, T. et al. Mechanistic features associated with improvement in mitral regurgitation after cardiac resynchronization therapy and their relation to long-term patient outcome. Circ. Heart. Fail. 6, 685–693 (2013).
Van Bommel, R. J. et al. Cardiac resynchronization therapy as a therapeutic option in patients with moderate-severe functional mitral regurgitation and high operative risk. Circulation 124, 912–919 (2011).
Castillo, J. G., Anyanwu, A. C., El-Eshmawi, A. & Adams, D. H. All anterior and bileaflet mitral valve prolapses are repairable in the modern era of reconstructive surgery. Eur. J. Cardiothorac. Surg. 45, 139–145 (2014).
Castillo, J. G., Anyanwu, A. C., Fuster, V. & Adams, D. H. A near 100% repair rate for mitral valve prolapse is achievable in a reference center: implications for future guidelines. J. Thorac. Cardiovasc. Surg. 144, 308–312 (2012).
Watt, T. M. F. et al. Degenerative mitral valve repair restores life expectancy. Ann. Thorac. Surg. 109, 794–801 (2020).
Coutinho, G. F., Correia, P. M., Branco, C. & Antunes, M. J. Long-term results of mitral valve surgery for degenerative anterior leaflet or bileaflet prolapse: analysis of negative factors for repair, early and late failures, and survival. Eur. J. Cardiothorac. Surg. 50, 66–74 (2016).
Dillon, J. et al. Comparative long-term results of mitral valve repair in adults with chronic rheumatic disease and degenerative disease: is repair for “burnt-out” rheumatic disease still inferior to repair for degenerative disease in the current era? J. Thorac. Cardiovasc. Surg. 149, 771–777 (2015).
Kanemitsu, H., Nakamura, K., Fukunaga, N. & Koyama, T. Long-term outcomes of mitral valve repair for active endocarditis. Circ. J. 80, 1148–1152 (2016).
Schnittman, S. R. et al. Survival and long-term outcomes after mitral valve replacement in patients aged 18 to 50 years. J. Thorac. Cardiovasc. Surg. 155, 96–102 (2018).
Wu, A. H. et al. Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. J. Am. Coll. Cardiol. 45, 381–387 (2005).
De Bonis, M. et al. Long-term results of mitral repair in patients with severe left ventricular dysfunction and secondary mitral regurgitation: does the technique matter? Eur. J. Cardiothorac. Surg. 50, 882–889 (2016).
Stone, G. W. et al. Transcatheter mitral-valve repair in patients with heart failure. N. Engl. J. Med. 379, 2307–2318 (2018). This paper reports the results of the COAPT trial in patients with heart failure and moderate-to-severe or severe secondary mitral regurgitation who remained symptomatic despite the use of maximal doses of guideline-directed medical therapy, randomly assigned to be treated or not by transcatheter mitral valve repair.
Rosenhek, R. et al. Outcome of watchful waiting in asymptomatic severe mitral regurgitation. Circulation 113, 2238–2244 (2006).
Uretsky, S. et al. Discordance between echocardiography and MRI in the assessment of mitral regurgitation severity: a prospective multicenter trial. J. Am. Coll. Cardiol. 65, 1078–1088 (2015).
Adams, D. H., Rosenhek, R. & Falk, V. Degenerative mitral valve regurgitation: best practice revolution. Eur. Heart J. 31, 1958–1966 (2010).
Bortolotti, U., Milano, A. D. & Frater, R. W. Mitral valve repair with artificial chordae: a review of its history, technical details, long-term results, and pathology. Ann. Thorac. Surg. 93, 684–691 (2012).
Falk, V. et al. How does the use of polytetrafluoroethylene neochordae for posterior mitral valve prolapse (loop technique) compare with leaflet resection? A prospective randomized trial. J. Thorac. Cardiovasc. Surg. 136, 1205 (2008).
Suri, R. M. et al. Effect of recurrent mitral regurgitation following degenerative mitral valve repair: long-term analysis of competing outcomes. J. Am. Coll. Cardiol. 67, 488–498 (2016). This paper demonstrates how recurrent mitral regurgitation following degenerative mitral valve repair is associated with adverse LV remodelling and late death, highlighting the need to refer complex mitral valve prolapse to centres of excellence.
Lazam, S. et al. Twenty-year outcome after mitral repair versus replacement for severe degenerative mitral regurgitation: analysis of a large, prospective, multicenter, international registry. Circulation 135, 410–422 (2017).
Gammie, J. S., O’Brien, S. M., Griffith, B. P., Ferguson, T. B. & Peterson, E. D. Influence of hospital procedural volume on care process and mortality for patients undergoing elective surgery for mitral regurgitation. Circulation 115, 881–887 (2007).
De Bonis, M. et al. Very long-term durability of the edge-to-edge repair for isolated anterior mitral leaflet prolapse: up to 21 years of clinical and echocardiographic results. J. Thorac. Cardiovasc. Surg. 148, 2027–2032 (2014). This paper shows how mitral valve repair can ensure excellent long-term results when performed in high-volume centres of excellence.
David, T. E., Armstrong, S. & Ivanov, J. Chordal replacement with polytetrafluoroethylene sutures for mitral valve repair: a 25-year experience. J. Thorac. Cardiovasc. Surg. 145, 1563–1569 (2013).
Di Bardino, D. J. et al. Four decades of experience with mitral valve repair: analysis of differential indications, technical evolution, and long-term outcome. J. Thorac. Cardiovasc. Surg. 139, 76–83 (2010).
Bonow, R. O. & Adams, D. H. The time has come to define centers of excellence in mitral valve repair. J. Am. Coll. Cardiol. 67, 499–501 (2016).
Obadia, J. F. et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. N. Engl. J. Med. 379, 2297–2306 (2018). This paper reports the results of the MITRA-FR trial in patients with severe secondary mitral regurgitation and chronic heart failure who were randomly assigned to be treated with percutaneous mitral valve repair in addition to medical therapy or with medical therapy alone.
Grossi, E. A. et al. Outcomes of coronary artery bypass grafting and reduction annuloplasty for functional ischemic mitral regurgitation: a prospective multicenter study (Randomized Evaluation of a Surgical Treatment for Off-Pump Repair of the Mitral Valve). J. Thorac. Cardiov. Sur. 141, 91–97 (2011).
Fattouch, K. et al. POINT: efficacy of adding mitral valve restrictive annuloplasty to coronary artery bypass grafting in patients with moderate ischemic mitral valve regurgitation: a randomized trial. J. Thorac. Cardiov. Sur. 138, 278–285 (2009).
Smith, P. K. et al. Surgical treatment of moderate ischemic mitral regurgitation. N. Engl. J. Med. 371, 2178–2188 (2014).
Michler, R. E. et al. Two-year outcomes of surgical treatment of moderate ischemic mitral regurgitation. N. Engl. J. Med. 374, 1932–1941 (2016).
Onorati, F. et al. Midterm clinical and echocardiographic results and predictors of mitral regurgitation recurrence following restrictive annuloplasty for ischemic cardiomyopathy. J. Thorac. Cardiov. Surg. 138, 654–662 (2009).
Goldstein, D. et al. Two-year outcomes of surgical treatment of severe ischemic mitral regurgitation. N. Engl. J. Med. 374, 344–353 (2016).
Abbott. Breakthrough TMVr therapy for select patients with mitral regurgitation (MR). Structural Heart Solutions https://www.structuralheartsolutions.com/structural-heart-products-solutions/mitral-valve-mitraclip/overview/ (2019).
Feldman, T. et al. Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort. J. Am. Coll. Cardiol. 54, 686–694 (2009).
Mauri, L. et al. Four-year results of a randomized controlled trial of percutaneous repair versus surgery for mitral regurgitation. J. Am. Coll. Cardiol. 62, 317–328 (2013).
Sorajja, P. et al. Outcomes with transcatheter mitral valve repair in the United States: an STS/ACC TVT registry report. J. Am. Coll. Cardiol. 70, 2315–2327 (2017).
Puls, M. et al. One-year outcomes and predictors of mortality after MitraClip therapy in contemporary clinical practice: results from the German transcatheter mitral valve interventions registry. Eur. Heart J. 37, 703–712 (2016).
Feldman, T. et al. Percutaneous repair or surgery for mitral regurgitation. N. Engl. J. Med. 364, 1395–1406 (2011).
Glower, D. D. et al. Percutaneous mitral valve repair for mitral regurgitation in high-risk patients: results of the EVEREST II study. J. Am. Coll. Cardiol. 64, 172–181 (2014).
Praz, F. et al. Mitral regurgitation in heart failure: time for a rethink. Eur. Heart J. 40, 2189–2193 (2019).
Senni, M., Adamo, M., Metra, M., Alfieri, O. & Vahanian, A. Treatment of functional mitral regurgitation in chronic heart failure: can we get a ‘proof of concept’ from the MITRA-FR and COAPT trials? Eur. J. Heart Fail. 21, 852–861 (2019).
Stone, G. W. & Alfieri, O. The five Ws of transcatheter mitral valve repair: who, what, when, where, and why. EuroIntervention. 15, 837–840 (2019).
Packer, M. & Grayburn, P. A. Contrasting effects of pharmacological, procedural, and surgical interventions on proportionate and disproportionate functional mitral regurgitation in chronic heart failure. Circulation 140, 779–789 (2019).
Buzzatti, N. et al. Mid-term outcomes (up to 5 years) of percutaneous edge-to-edge mitral repair in the real-world according to regurgitation mechanism: a single-center experience. Catheter. Cardiovasc. Interv. 94, 427–435 (2019).
Lim, D. S. et al. Transcatheter valve repair for patients with mitral regurgitation: 30-day results of the CLASP study. JACC Cardiovasc. Interv. 12, 1369–1378 (2019).
Gammie, J. S. et al. Beating-heart mitral valve repair using a novel ePTFE cordal implantation device: a prospective trial. J. Am. Coll. Cardiol. 71, 25–36 (2018).
Seeburger, J. et al. Off-pump transapical implantation of artificial neo-chordae to correct mitral regurgitation: the TACT trial (Transapical Artificial Chordae Tendinae) proof of concept. J. Am. Coll. Cardiol. 63, 914–919 (2014).
Colli, A. et al. Transapical off-pump mitral valve repair with NeoChord implantation: early clinical results. Int. J. Cardiol. 204, 23–28 (2016).
Colli, A. et al. An early European experience with transapical off-pump mitral valve repair with NeoChord implantation. Eur. J. Cardiothorac. Surg. 54, 460–466 (2018).
Nickenig, G. et al. Treatment of chronic functional mitral valve regurgitation with a percutaneous annuloplasty system. J. Am. Coll. Cardiol. 67, 2927–2936 (2016).
Nickenig, G. et al. Transcatheter mitral annuloplasty in chronic functional mitral regurgitation: 6-month results with the Cardioband percutaneous mitral repair system. JACC Cardiovasc. Interv. 9, 2039–2047 (2016).
Bail, D. H. Treatment of functional mitral regurgitation by percutaneous annuloplasty using the Carillon mitral contour system — currently available data state. J. Interv. Cardiol. 30, 156–162 (2017).
Sorajja, P., Cavalcante, J. L. & Gössl, M. The need for transcatheter mitral valve replacement. J. Am. Coll. Cardiol. 73, 1247–1249 (2019).
Taramasso, M., Gavazzoni, M., Nickenig, G. & Maisano, F. Transcatheter mitral repair and replacement: which procedure for which patient? EuroIntervention 15, 867–874 (2019).
Sorajja, P. et al. Novel transcatheter mitral valve prosthesis for patients with severe mitral annular calcification. J. Am. Coll. Cardiol. 74, 1431–1440 (2019).
Regueiro, A., Granada, J. F., Dagenais, F. & Rodés-Cabau, J. Transcatheter mitral valve replacement: insights from early clinical experience and future challenges. J. Am. Coll. Cardiol. 69, 2175–2192 (2017).
Del Val, D. et al. Early experience with transcatheter mitral valve replacement: a systematic review. J. Am. Heart. Assoc. 8, e013332 (2019).
Stoler, R. C. et al. Transcatheter mitral valve replacement for patients with symptomatic mitral regurgitation: a global feasibility trial. J. Am. Coll. Cardiol. 69, 381–391 (2017).
Mehaffey, H. J. et al. Contemporary outcomes in reoperative mitral valve surgery. Heart 104, 652–656 (2018).
Eleid, M. F. et al. Percutaneous transvenous transseptal transcatheter valve implantation in failed bioprosthetic mitral valves, ring annuloplasty, and severe mitral annular calcification. JACC Cardiovasc. Interv. 9, 1161–1174 (2016).
Ye, J. et al. Transcatheter aortic and mitral valve-in-valve implantation for failed surgical bioprosthetic valves: an eight-year single-center experience. JACC Cardiovasc. Interv. 8, 1735–1744 (2015).
Alkhouli, M. et al. Transcatheter and surgical management of mitral paravalvular leak: long-term outcomes. JACC Cardiovasc. Interv. 10, 1946–1956 (2017).
Chikwe, J. et al. Relation of mitral valve surgery volume to repair rate, durability, and survival. J. Am. Coll. Cardiol. 69, 2397–2406 (2017).
Chiarito, M. et al. Outcome after percutaneous edge-to-edge mitral repair for functional and degenerative mitral regurgitation: a systematic review and meta-analysis. Heart. 104, 306–312 (2018).
Buzzatti, N. et al. Comparison of outcomes of percutaneous MitraClip versus surgical repair or replacement for degenerative mitral regurgitation in octogenarians. Am. J. Cardiol. 115, 487–492 (2015).
Goliasch, G. et al. Refining the prognostic impact of functional mitral regurgitation in chronic heart failure. Eur. Heart J. 39, 39–46 (2018). This paper shows that in patients receiving optimal medical therapy, the adverse prognostic effect of secondary mitral regurgitation occurs predominantly in a subgroup of patients with a specific intermediate heart failure phenotype.
Braun, D., Näbauer, M., Massberg, S. & Hausleiter, J. One-stop shop: simultaneous direct mitral annuloplasty and percutaneous mitral edge-to-edge repair in a patient with severe mitral regurgitation. Catheter. Cardiovasc. Interv. 93, E318–E319 (2019).
Ferrazzi, P. et al. Transaortic chordal cutting: mitral valve repair for obstructive hypertrophic cardiomyopathy with mild septal hypertrophy. J. Am. Coll. Cardiol. 66, 1687–1696 (2015).
Sado, D. M. et al. Myectomy plus Alfieri technique for outflow tract obstruction in hypertrophic cardiomyopathy. Circulation 122, 938–939 (2010).
Aphram, G. et al. Re-repair of the failed mitral valve: insights into aetiology and surgical management. Eur. J. Cardiothorac. Surg. 54, 774–780 (2018).
Allende, R. et al. Transcatheter mitral “valve-in-ring” implantation: a word of caution. Ann. Thorac. Surg. 99, 1439–1442 (2015).
Grayburn, P. A., Sannino, A. & Packer, M. Proportionate and disproportionate functional mitral regurgitation: a new conceptual framework that reconciles the results of the MITRA-FR and COAPT trials. JACC Cardiovasc. Imaging 12, 353–362 (2019). This paper addresses the novel concept of proportionate and disproportionate functional mitral regurgitation in chronic heart failure.
O.A. is President of the Alfieri Heart Foundation, which aims to encourage training, innovation and research in structural heart disease.
The authors declare no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Del Forno, B., De Bonis, M., Agricola, E. et al. Mitral valve regurgitation: a disease with a wide spectrum of therapeutic options. Nat Rev Cardiol 17, 807–827 (2020). https://doi.org/10.1038/s41569-020-0395-7